Dr. Jung is Associate Director for Policy & Communications of the Office of Drug Security, Integrity, & Recalls in FDA’s Center for Drug Evaluation & Research, Office of Compliance. She develops policy & regulatory strategies to protect the supply chain from counterfeit & other substandard drugs.
Joined OCI in 1997, Special Agent in the DC Field Office. Since 2004 he has been a Sr Operations Mgr for drug investigations coordinating OCI counterfeit drug and prescription drug diversion investigations and assisting OCI Special Agents conducting these and other FDA related drug investigations
Christa Wirthumer-Hoche studied biochemistry TU Vienna, doctoral thesis at Medical Physiology. Starting at the AT Nat. Inst. for Quality Control of Drugs - quality assessment, Head of Regulatory Affairs in the Ministry of Health, Now Head of Licensing of Med Products and Deputy Head of the Austrian
Description
This town hall is intended to be an open forum discussion on the risks to human drugs created by complex global supply chains, greater foreign sourcing of products and the increase in volume of imports along with current efforts by regulators and industry to ensure product safety and quality.
Learning Objectives: Describe the impact of globalization and the various threats and vulnerabilities to the human drug supply chain Describe challenges and regulatory efforts underway for drug security and protection of public health Discuss collaborative private sector efforts to assure the safe transit of drugs.